MRKR Annual Cash & Cash Equivalents
$15.11 M
+$3.33 M+28.26%
31 December 2023
Summary:
As of January 22, 2025, MRKR annual cash & cash equivalents is $15.11 million, with the most recent change of +$3.33 million (+28.26%) on December 31, 2023. During the last 3 years, it has fallen by -$6.24 million (-29.23%). MRKR annual cash & cash equivalents is now -75.53% below its all-time high of $61.75 million, reached on December 31, 2018.MRKR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRKR Quarterly Cash And Cash Equivalents
$9.00 M
+$1.20 M+15.37%
30 September 2024
Summary:
As of January 22, 2025, MRKR quarterly cash and cash equivalents is $9.00 million, with the most recent change of +$1.20 million (+15.37%) on September 30, 2024. Over the past year, it has increased by +$1.20 million (+15.37%). MRKR quarterly cash and cash equivalents is now -86.05% below its all-time high of $64.51 million, reached on March 31, 2021.MRKR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRKR Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +28.3% | +15.4% |
| 3 y3 years | -29.2% | +15.4% |
| 5 y5 years | -75.5% | -72.0% |
MRKR Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -64.3% | +28.3% | -78.8% | +40.6% |
| 5 y | 5-year | -65.6% | +28.3% | -86.0% | +40.6% |
| alltime | all time | -75.5% | >+9999.0% | -86.0% |
Marker Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $9.00 M(+15.4%) |
| June 2024 | - | $7.80 M(-31.1%) |
| Mar 2024 | - | $11.32 M(-25.1%) |
| Dec 2023 | $15.11 M(+28.3%) | $15.11 M(-13.5%) |
| Sept 2023 | - | $17.47 M(-3.6%) |
| June 2023 | - | $18.12 M(+183.1%) |
| Mar 2023 | - | $6.40 M(-45.7%) |
| Dec 2022 | $11.78 M(-72.2%) | $11.78 M(-34.8%) |
| Sept 2022 | - | $18.08 M(-30.0%) |
| June 2022 | - | $25.82 M(-9.8%) |
| Mar 2022 | - | $28.64 M(-32.4%) |
| Dec 2021 | $42.35 M(+98.3%) | $42.35 M(-13.0%) |
| Sept 2021 | - | $48.71 M(-14.9%) |
| June 2021 | - | $57.22 M(-11.3%) |
| Mar 2021 | - | $64.51 M(+202.1%) |
| Dec 2020 | $21.35 M(-51.4%) | $21.35 M(-20.8%) |
| Sept 2020 | - | $26.96 M(-16.1%) |
| June 2020 | - | $32.12 M(-20.2%) |
| Mar 2020 | - | $40.26 M(-8.3%) |
| Dec 2019 | $43.90 M(-28.9%) | $43.90 M(-9.4%) |
| Sept 2019 | - | $48.48 M(-9.3%) |
| June 2019 | - | $53.44 M(-7.4%) |
| Mar 2019 | - | $57.71 M(-6.5%) |
| Dec 2018 | $61.75 M(+1103.8%) | $61.75 M(+1337.9%) |
| Sept 2018 | - | $4.29 M(-44.8%) |
| June 2018 | - | $7.78 M(+177.9%) |
| Mar 2018 | - | $2.80 M(-45.4%) |
| Dec 2017 | $5.13 M(-34.7%) | $5.13 M(-32.6%) |
| Sept 2017 | - | $7.61 M(-23.6%) |
| June 2017 | - | $9.96 M(+68.1%) |
| Mar 2017 | - | $5.93 M(-24.5%) |
| Dec 2016 | $7.85 M(+19.4%) | $7.85 M(-18.1%) |
| Sept 2016 | - | $9.59 M(+154.4%) |
| June 2016 | - | $3.77 M(-34.2%) |
| Mar 2016 | - | $5.72 M(-13.0%) |
| Dec 2015 | $6.58 M(+4534.7%) | $6.58 M(+8.0%) |
| Sept 2015 | - | $6.09 M(+96.0%) |
| June 2015 | - | $3.11 M(+113.6%) |
| Mar 2015 | - | $1.45 M(+924.3%) |
| Dec 2014 | $141.90 K(+192.0%) | $141.90 K(-76.9%) |
| Sept 2014 | - | $613.60 K(+2878.6%) |
| June 2014 | - | $20.60 K(-78.0%) |
| Mar 2014 | - | $93.60 K(+92.6%) |
| Dec 2013 | $48.60 K(+43.8%) | $48.60 K(+891.8%) |
| Sept 2013 | - | $4900.00(-89.2%) |
| June 2013 | - | $45.20 K(+927.3%) |
| Mar 2013 | - | $4400.00(-87.0%) |
| Dec 2012 | $33.80 K | $33.80 K(+813.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $3700.00(-69.2%) |
| June 2012 | - | $12.00 K(-49.6%) |
| Mar 2012 | - | $23.80 K(-90.5%) |
| Dec 2011 | $250.20 K(+964.7%) | $250.20 K(+619.0%) |
| Sept 2011 | - | $34.80 K(+140.0%) |
| June 2011 | - | $14.50 K(-61.3%) |
| Mar 2011 | - | $37.50 K(+59.6%) |
| Dec 2010 | $23.50 K(-83.4%) | $23.50 K(-83.8%) |
| Sept 2010 | - | $144.70 K(-67.9%) |
| June 2010 | - | $450.30 K(+2004.2%) |
| Mar 2010 | - | $21.40 K(-84.9%) |
| Dec 2009 | $141.40 K(>+9900.0%) | $141.40 K(+206.1%) |
| Sept 2009 | - | $46.20 K(+298.3%) |
| June 2009 | - | $11.60 K(+146.8%) |
| Mar 2009 | - | $4700.00(+370.0%) |
| Dec 2008 | $1000.00(-99.4%) | $1000.00(-58.3%) |
| Sept 2008 | - | $2400.00(-91.7%) |
| June 2008 | - | $28.90 K(+48.2%) |
| Mar 2008 | - | $19.50 K(-88.4%) |
| Dec 2007 | $167.50 K(+39.1%) | $167.50 K(+26.8%) |
| Sept 2007 | - | $132.10 K(+196.2%) |
| June 2007 | - | $44.60 K(-78.4%) |
| Mar 2007 | - | $206.50 K(+71.5%) |
| Dec 2006 | $120.40 K(+114.2%) | $120.40 K(-66.1%) |
| Sept 2006 | - | $355.00 K(+166.9%) |
| June 2006 | - | $133.00 K(-37.8%) |
| Mar 2006 | - | $213.90 K(+280.6%) |
| Dec 2005 | $56.20 K(+384.5%) | $56.20 K(-27.9%) |
| Sept 2005 | - | $77.90 K(-61.5%) |
| June 2005 | - | $202.60 K(-75.1%) |
| Mar 2005 | - | $813.40 K(+6912.1%) |
| Dec 2004 | $11.60 K(-40.5%) | $11.60 K(-59.4%) |
| Sept 2004 | - | $28.60 K(-80.3%) |
| June 2004 | - | $145.00 K(+714.6%) |
| Mar 2004 | - | $17.80 K(-8.7%) |
| Dec 2003 | $19.50 K(-97.0%) | $19.50 K(-76.6%) |
| Sept 2003 | - | $83.30 K(+80.3%) |
| June 2003 | - | $46.20 K(-87.7%) |
| Mar 2003 | - | $375.40 K(-41.6%) |
| Dec 2002 | $642.60 K(+1373.9%) | $642.60 K(+257.8%) |
| June 2002 | - | $179.60 K(>+9900.0%) |
| Mar 2002 | - | $500.00(>+9900.0%) |
| Sept 2001 | - | $0.00(-100.0%) |
| June 2001 | - | $400.00(-42.9%) |
| Mar 2001 | - | $700.00(-89.2%) |
| Sept 2000 | - | $6500.00(-92.6%) |
| June 2000 | - | $87.80 K(+3.5%) |
| Mar 2000 | - | $84.80 K |
| Dec 1999 | $43.60 K | - |
FAQ
- What is Marker Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Marker Therapeutics?
- What is Marker Therapeutics annual cash & cash equivalents year-on-year change?
- What is Marker Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Marker Therapeutics?
- What is Marker Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Marker Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of MRKR is $15.11 M
What is the all time high annual cash & cash equivalents for Marker Therapeutics?
Marker Therapeutics all-time high annual cash & cash equivalents is $61.75 M
What is Marker Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, MRKR annual cash & cash equivalents has changed by +$3.33 M (+28.26%)
What is Marker Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of MRKR is $9.00 M
What is the all time high quarterly cash and cash equivalents for Marker Therapeutics?
Marker Therapeutics all-time high quarterly cash and cash equivalents is $64.51 M
What is Marker Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, MRKR quarterly cash and cash equivalents has changed by +$1.20 M (+15.37%)